Teva Pharma (TEVA) Launches Generic Actos Tabs
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Up)
Trade TEVA Now!
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has launched an authorized generic of Actos (pioglitazone-hydrochloride tablets) 15, 30 and 45mg.
Actos is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30, 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Actos is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30, 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
- Bloomin' Brands (BLMN) Prices 19M Common Stock Secondary Offering
- VIVUS, Inc. (VVUS) to Make Several Scientific Presentations in May
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
